Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Chronic fatigue syndrome: 3 cases and a discussion of the natural history of attention-deficit/hyperactivity disorder.

Young JL.

Postgrad Med. 2013 Jan;125(1):162-8. doi: 10.3810/pgm.2013.01.2631.

PMID:
23391682
2.
3.
4.
5.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
7.

Attention-deficit hyperactivity disorder.

Calis KA, Grothe DR, Elia J.

Clin Pharm. 1990 Aug;9(8):632-42. Review. Erratum in: Clin Pharm 1991 Apr;10(4):261.

PMID:
1974836
8.

Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting.

Jensen PS.

Am J Manag Care. 2009 May;15(5 Suppl):S129-40. Review.

9.

Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).

[No authors listed]

NIH Consens Statement. 1998 Nov 16-18;16(2):1-37. Review.

PMID:
10868163
10.
11.

Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey.

Lensing MB, Zeiner P, Sandvik L, Opjordsmoen S.

J Clin Psychiatry. 2013 Jan;74(1):e87-93. doi: 10.4088/JCP.12m07714.

PMID:
23419235
12.

Attention-deficit hyperactivity disorder in chronic fatigue syndrome patients.

Sáez-Francàs N, Alegre J, Calvo N, Antonio Ramos-Quiroga J, Ruiz E, Hernández-Vara J, Casas M.

Psychiatry Res. 2012 Dec 30;200(2-3):748-53. doi: 10.1016/j.psychres.2012.04.041. Epub 2012 May 28.

PMID:
22648008
13.

[Attention deficit-hyperactivity disorder (ADHD); etiology, diagnosis and treatment].

't Jong GW, van den Anker JN.

Ned Tijdschr Geneeskd. 2000 Nov 11;144(46):2227-8. Dutch. No abstract available.

PMID:
11103263
14.

[Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].

Käypä hoito suosituksen päivitystiivistelmä.

Duodecim. 2012;128(5):539-40. Finnish.

PMID:
22486070
15.

Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.

Walitza S, Melfsen S, Herhaus G, Scheuerpflug P, Warnke A, Müller T, Lange KW, Gerlach M.

J Neural Transm Suppl. 2007;(72):311-5.

PMID:
17982908
16.

Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.

Fone KC, Nutt DJ.

Curr Opin Pharmacol. 2005 Feb;5(1):87-93. Review.

PMID:
15661631
17.
18.

Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

Wigal T, Brams M, Gasior M, Gao J, Giblin J.

Postgrad Med. 2011 Mar;123(2):169-76. doi: 10.3810/pgm.2011.03.2275.

PMID:
21474905
19.

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.

Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.

J Am Acad Child Adolesc Psychiatry. 2011 Apr;50(4):395-405. doi: 10.1016/j.jaac.2011.01.007. Epub 2011 Mar 3.

PMID:
21421179
20.

Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.

Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ.

J Dev Behav Pediatr. 2006 Feb;27(1):1-10.

PMID:
16511362

Supplemental Content

Support Center